Currently, a significant number of products are in development for the treatment of arthritis and arthritis-associated pain. Datamonitor expects this will lead to a saturation of the market over the next seven years as drugs with similar modes of action compete for a share of a patient population that is not expected to expand to meet the available supply of treatments. Competition within this market looks set to increase dramatically. Drugs of Tomorrow 2000: Arthritis provides an in-depth analysis of the arthritis pipeline products and forecasts their performance to 2007. The report provides comprehensive coverage of all phase II and phase III treatments under development to treat rheumatoid arthritis and osteoarthritis, and the pain associated with these conditions. Also, the current and future commercial attractiveness of these drugs is assessed.
